Cargando…
Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience
INTRODUCTION: Relapse is common after treatment discontinuation for patients with moderate-to-severe psoriasis. The objective of this study was to understand the remission duration and long-term outcomes in psoriasis patients after biologic withdrawal. METHODS: We retrospectively included the follow...
Autores principales: | Huang, Yi-Wei, Tsai, Tsen-Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704191/ https://www.ncbi.nlm.nih.gov/pubmed/31270683 http://dx.doi.org/10.1007/s13555-019-0310-5 |
Ejemplares similares
-
The Impact of Tofacitinib on Quality of Life in Patients with Moderate-to-Severe Psoriasis- An Observational Study
por: Mohta, Alpana, et al.
Publicado: (2023) -
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
por: Di Lernia, V, et al.
Publicado: (2016) -
Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
por: Peterson, Danielle M., et al.
Publicado: (2021) -
Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022) -
Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
por: Travaglini, Massimo, et al.
Publicado: (2023)